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Abstract:   Patients with advanced cancer frequently express positive attitudes and can be unduly 
optimistic about the potential benefits of treatment. In order to evaluate an illusory domain in the 
context of advanced cancer, we developed a scale of will to live and characterized the beliefs that 
patients held about the curability of their cancer, and how committed they were to using alternative 
treatments. A measure of quality of life was used as the dependent variable in order to assess the 
association between these attributes. After a preliminary exploration confirmed the presence of an 
illusory 
domain, these concepts were prospectively tested in 149 ambulant patients with advanced cancer who 
attended for palliative systemic treatment, radiation treatment or supportive care. The scale of global 
quality of life was reliable (Cronbach’s alpha coefficient 0.72). The distribution of the scores of will to 
live was skewed, with no respondent scoring poorly, and the scale was reliable (Cronbach’s alpha 
coefficient 0.82). The scale of belief in curability showed diverse beliefs. In some cases, there was a 
discrepancy between respondents’ beliefs in curability and what they 
believed to be the report by their doctors. There was also an association between a committed use of 
alternative treatments and a belief in the curability of the cancer (p50.001). In a multiple regression 
analysis, both will to live and performance status remained associated with better quality of life scores 
after adjustment for other relevant variables (p50.05 and 50.001, respectively). These results suggest 
that positive illusory beliefs can be measured and are an important component of adaption for some 
patients with advanced cancer. Furthermore, this illusory domain 
may influence the perception and measurement of quality of life.  
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INTRODUCTION 
 
What do patients with advanced cancer believe about their prognosis and how do they 
respond? In psychosocial research, studies of healthy people recognize that positive 
illusory beliefs may contribute to satisfaction with life (Taylor and Brown, 
1988). Since some patients with advanced cancer express optimistic views in the face 
of declining health and a limited lifespan, illusory attitudes towards their illness and 
beliefs about the outcome of treatments could influence their perception of quality of 
life. To date, there has been little evaluation of the consequences of illusory beliefs in 
patients with advanced cancer and none about their impact on the perception of 
quality of life. Numerous scales of quality of life have been developed and refined 
over the last two decades, and the measurement of quality of life is now regarded as 
an important end-point of clinical trials evaluating the efficacy of treatments for 
cancer (Moinpour et al., 1989; Aaronson et al., 
 
1993; Slevin et al., 1988). The historical foundation of scale development has 
emphasized measures of symptoms, functional capacity, psychological and 
emotional health, and social activity (Najman and Levine, 1981; Donovan et al., 
1989) but, in cancer clinical trials, quality of life is typically conceptualized in terms 
of functional activity and the status of symptoms (Aaronson et al., 1993; Cella et al., 
1993), with an evolving focus on the development of disease and treatment specific 
subscales (Bjordal et al., 1994; List et al., 1996). However, quality of life is a 
multidimensional construct that goes beyond the impact of a cancer and its treatment 
on symptoms and functional status, and is best viewed as a subjective evaluation of 
life as a whole and a comparison with what is ideal or possible (De Haes, 1988; Cella 
and Cherin, 1988). This global view of quality of life implies a perceived satisfaction 
with life in comparison with healthy people and in terms of future expectations. Such 
an interpretation acknowledges a potential contribution of positive illusions to 
the perception of quality of life and challenges the inference of a causal relationship 
between improvements of symptomatic and functional activity scores with global 
quality of life measures. 
 
The objectives of this study were the exploration and characterization of an illusory 
domain of thought and action in patients with advanced cancer, and an evaluation of 
the relationship between this illusory domain and quality of life. In order to determine 
the feasibility of characterizing illusory concepts, this study was divided into two 
phases. The first phase explored concepts of global quality of life conceptualized in 
terms of happiness and satisfaction, and evaluated the domains of depression, social 
experiences and function as well as measures of symptoms. A qualitative and 
quantitative analysis also explored the concept of will to live and the use of 
alternatives to conventional medical treatment. In the second phase, these concepts 
were prospectively tested in patients with advanced cancer who were in reasonably 
good general condition and therefore judged as not being in an immediately 
terminal phase of their illness (Yates et al., 1993). These patients were potential 
candidates for active treatment of their cancer and could gain palliative benefit from a 
response, but not cure. As a result, these patients were in a position to hold and 
express positive illusions about the benefits of treatment. 
 
 
 
FIRST PHASE OF STUDY}EXPLORATION OF CONCEPTS METHODS 
 
The primary goal of the first phase of the study was to identify, qualitatively and 
quantitatively, valid and reliable measures of the conceptual domains of quality of 
life, and patient beliefs and attitudes about the diagnosis and experience of 
cancer. A 143-item questionnaire was administered to 85 ambulant patients who 
attended the South Brisbane Oncology Research Unit, Princess Alexandra 
Hospital, and the Wesley Cancer Care Centre. All patients were informed of the 
purpose of this study and written informed consent was provided in accordance with 
the Ethics Committees of the respective institutions. Participants of this study were 
being treated with palliative or curative intent. Based on the conceptual model of 
Ware (1984) for assessing the impact of a disease on quality of life, a questionnaire 
was developed to reflect the conceptually distinct facets of physical, psychological 
and social life affected by cancer and its treatment. The questionnaire included scales 
to evaluate physical symptoms, depression and social experiences, networks and 
functions. Scales of  attitudes to, and satisfaction with, treatments were also 
developed on the basis of the clinical experience of the oncologists involved in this 
study. In addition, general attitudinal questions examined the impact of a personal 
experience of cancer. This included 40 items which assessed patients’ beliefs about 
the future, their feelings and experiences. Scales of global quality of life (Bradburn, 
1969; Campbell et al., 1976; Coates et al., 1976; de Haes and Van Knippenberg, 
1985; 
 
Ferrans, 1990) and depression (Bedford and Foulds, 1977) were derived from the 
literature and adapted to emphasize an evaluation of the concept of quality of life in 
terms of satisfaction with life and a sense of well being as a whole, rather than 
published measures that emphasized morbidity and functional status. A series of 
factor analyses and correlational analyses of all items comprising the various beliefs, 
attitudes, experiences and quality of life were then undertaken to facilitate the 
development of multi-item scales that measured the concepts of interest (Carmines 
and Zeller, 1979). Cronbach’s alpha coefficients were calculated to assess the internal 
consistency of the identified scales (Cronbach, 1951). In addition, 
 
  
 
 
all participants were interviewed in depth after completing the questionnaire to assess 
the face and content validity of the items. 
 
RESULTS 
 
Eleven scales were developed from the database of the pilot questionnaire utilizing 
factor analysis and reliability testing. Seven scales assessed the various physical, 
psychological and social domains that may be affected by cancer and its treatment. 
Three scales assessed various attitudes associated with the experience of cancer, and 
one scale assessed global quality of life. Table 1 summarizes the psychometric 
properties of the scales assessing physical symptoms, depression, social experiences, 
attitudes to alternative treatments, confidence in treatments, will to live and global 
quality of life. Detailed interviews of all participants followed completion of the 
questionnaire and the results suggested that a strongly held belief in curability 
and will to live, and a committed use of alternatives to conventional medical treatment 
clustered into an illusory domain. The final profile of the quantitative results and the 
subsequent qualitative assessment of the face and content validity of the scales 
provided confidence to to test this illusory domain and its potential contribution 
to the perception of quality of life in a group of patients who were being treated with 
palliative intent. 
 
SECOND PHASE OF STUDY DEVELOPMENT OF CONCEPTS METHODS 
 
Design 
The goals of the second phase were to apply the measures developed in the first phase 
of the study to patients with advanced cancer, and to expand concepts identified in the 
qualitative and quantitative assessment of the first study. The current report is 
concerned only with these previously developed scales and new measures that 
contributed to positive illusions and overall quality of life. 
Ambulant patients attended the South Brisbane Oncology Research Unit, Princess 
Alexandra Hospital, and The Wesley Cancer Care Centre for palliative systemic 
treatment, radiation treatment or follow-up evaluation and supportive care. All 
patients attending these centres had been informed verbally about the extent of their 
cancer, its incurability, their limited life span, the palliative goal of treatment, the 
response to treatment and their overall progress prior to activation of this study. The 
plan was to prospectively identify and target all potentially eligible patients and to 
capture their immediate views about their cancer. To be eligible, patients had locally 
advanced or metastatic cancer, measurable or evaluable disease, an estimated survival 
between 3 months and 2 years, a performance status of ECOG 0-3, and a time interval 
since last review of less than 3 months. 
 
Sample 
During the 10-week period of this study, 178 consecutive patients potentially fulfilled 
the criteria for participation in this study. Four patients did not attend on the date of 
appointment. Sixteen patients refused to participate or declined to complete the 
questionnaire, and 6 patients were missed because of time constraints at the time of 
outpatient attendance. Three patients had an ECOG performance status of 4 at the 
time of administration of the questionnaire. The remaining 149 eligible patients 
formed the basis of this analysis. 
 
 
TABLE 2 
 
 
 
 
 
Instruments 
 
A 171-item self-administered questionnaire was designed to measure social, health 
and demographic factors, and to refine measures of the concepts developed from the 
first phase of the study. The demographic, health and treatment characteristics of the 
149 respondents are set out in Table 2. A four item scale of quality of life, derived 
from the first phase of the study, was utilized as the dependent variable in the analyses 
of this study (Table 3). This scale incorporated a time frame which avoided 
measurement of immediate mood. Three items reflected a ‘generalized nowadays’ 
time frame, and an additional item looked at the 
 
 
 
 
 
 
whole of life. Three measures were adapted from the first phase of the study to tap an 
illusory domain. The first measure comprised a five item version of the 13-item will 
to live scale developed in the first phase (Table 3). These five items were selected 
after factor analysis of the original 13-item scales suggested two possible sub-
scales}an eight item series of statements indicating a willingness of patients to have 
treatment in order to survive a cancer, and a five-item scale which was more 
representative of the core concept of will to live. The second measure included items 
measuring the respondents’ beliefs about the curability of their cancer (Table 3). One 
item assessed respondents’ recollections of what the doctor had told them about 
curability and two items assessed what the respondents themselves believed about 
curability. The latter two items were added to create an index of belief in curability. 
The third measure utilized a series of questions to examine the use of, and belief 
about, alternatives to conventional medical treatment. The development of these 
scales, which emphasized the degree of commitment of respondents to alternatives to 
conventional medical treatment, have been described elsewhere (Yates et al., 1993). 
To confirm the validity of the concepts detailed in this phase of the study, qualitative 
data were collected by the interviewers (PY and AC). Spontaneous comments by 
respondents were recorded in 91 cases by the interviewers and an additional 9 in-
depth interviews were conducted after completion of the questionnaire. Physicians 
also completed an assessment at the time of administration of the questionnaire. This 
assessment included the diagnosis, performance status, the progress of symptoms 
since the last assessment and the objective response to chemotherapy and/or 
endocrine treatment. The time interval since the last patient assessment ranged 
from 3 weeks to 3 months. Physicians rated the progress of cancer related symptoms 
as being stable, better or worse since the last assessment. 
The measurement of objective response utilized standard WHO guidelines (World 
Health Organisation, 1979) and the interval since the last assessment of objective 
response was at least 6 weeks and no more than 3 months. 
 
Data analysis 
Data were entered and analyzed utilizing the statistical package SPSS for Windows. 
The interitem correlation within individual concepts was obtained with a Cronbach’s 
alpha coefficient (Cronbach, 1951). A Kendall Taub was utilized to examine 
associations among items with ordered categories. A chi-square test was used to 
assess associations among categorical variables. Analysis of variance and multiple 
regression analyses of quality of life scores were used to test the association between 
the concepts of will to live, belief in curability and use of alternatives, with the 
quality of life as the outcome variable. Physician rated measures of performance 
score, status of symptoms and objective response to systemic treatment were also 
included as independent variables in the analysis of variance and the multivariate 
analysis of quality of life.  
 
RESULTS 
 
Each item on the quality of life scale had a score ranging from 1 (representing a 
measure of good quality of life) to 4 (a measure of poor quality of life). The 
Cronbach’s alpha coefficient of this scale was 0.72 (Table 3), with the four item scale 
having a potential range of 4–16 and an actual range of 4–12. In the subsequent 
analysis, responses were categorized as mean quality of life and good quality of life, 
the latter representing the top tertile of scores (Table 6). On a scale of 1 (strongly 
agree) to 5 (strongly disagree), respondents were asked to indicate how well the 
statements about will to live reflected their own beliefs. The Cronbach’s alpha 
coefficient for the will to live scale was 0.82 (Table 3). As in the first phase, there was 
a pronounced tendency for responses to agree with each statement, indicating that 
respondents differentiated between ‘strongly agreeing’ and ‘agreeing’. A summated 
scale was created having a potential range of 5, which represented a strong will to 
live, to 25, which represented a weak will to live. The actual responses ranged from 5 
to 19 and over half the respondents scored 5 or 6. For the purpose of further analysis, 
respondents were categorized into three approximately equal groups according to their 
scores on this scale (Table 6). Scale scores of 5 were categorized as having a very 
strong will to live, scores 6–9 as having a strong will to live, and scores 10–19 as 
having a moderate will to live. Belief in curability was assessed by two items that 
asked respondents to indicate if they believed that their cancer was curable. The 
responses to the two questions were coded to create an index with a potential and 
actual range of 2 (strongly held belief in curability) to 6 (belief that cancer was not 
curable). 
 
 
In the subsequent analysis, respondents were categorized into three groups based on 
their scores in these scales (Tables 4 and 6). These categories of belief in curability 
were designated as curable, uncertain and incurable. 
 
Table 4 sets out respondents’ beliefs about the curability of their cancer and their 
recollections of what doctors had told them about curability. Of the 145 evaluable 
responses to these questions, 39 respondents (27%) believed that their cancer was 
curable and 61 (42%) were uncertain. Only 45 respondents (31%) believed that their 
cancer was incurable. Of the 39 respondents who believed that their cancer was 
curable, 16 (41%) reported that their doctor had informed them of its curability but 
another 15 (38%) reported that the doctor had stated that their cancer was incurable. 
 
In general, there was an association between the beliefs of the 106 respondents who 
were uncertain of their chance of cure or who regarded their cancer as incurable, and 
their recollections of what the doctor had stated. Of this group, only 12 patients (11%) 
believed that their doctor had stated that the cancer was curable. 
In this study, 33 respondents were strongly committed to the use of alternative 
treatments in addition to conventional medical care. Since the promoted goal of many 
alternative treatments is cure, belief in curability was assessed according to 
the use of alternative treatments. The results in Table 5 show that committed users 
were more likely to believe that their cancers were curable than those respondents 
who did not use alternative treatments or who made only minimal changes to 
their lifestyle (p5 0.001). 
 
 
 
 
 
In order to explore the relationship between belief in curability, use of alternatives to 
conventional medical treatment and will to live, bivariate and multivariate analyses 
were conducted using quality of life as the reference construct. These analyses also 
included objective physician-rated measures known to be associated with measures of 
quality of life. 
able 6 shows an analysis of variance of mean quality of life scores, and a chi-square 
analysis of the top tertile scores of quality of life for these objective measures and 
tested concepts. For the purpose of this analysis, patients with an ECOG performance 
status of 2 and 3 were pooled.  There was a strong association between performance 
status and mean and top tertile quality of life scores. Objective response was 
determined by physicians in the 105 evaluable patients who were treated with 
cytotoxic or endocrine therapies. Although mean and top tertile quality of life scores 
appeared to be better in patients categorized as stable (49 patients) or responding (39 
patients) to treatment, this association was not statistically significant. The symptom 
status refers to the physician’s assessment as to whether symptoms had been 
progressing, stable or improving during the weeks since last out-patient visit. Quality 
of life scores correlated with the physician’s assessment of the status of symptoms 
(p50.01), and the percentage in the top tertile was significantly lower in those 
respondents whose symptoms were categorized as worse since the last assessment 
(p50.05). The trichotomized scale of will to live was associated with quality of life 
scores (p50.001), and the percentage in the top tertile was higher in those respondents 
categorized as having a very strong will to live (p50.01). Belief in curability was also  
associated with better quality of life scores and a higher percentage of respondents 
in the top tertile quality of life scores (p50.01 and 50.05, respectively), but there was 
 
 
 
 
 
 
no association between a committed use of alternative treatments and quality of life 
scores. When the six independent variables were entered into a multiple regression 
analysis, with quality of life scores as the dependent variable, will to live and 
performance status were again identified as significant independent predictors of 
quality of life, with sr2 of 0.18 and 0.30, respectively. The remaining variables were 
not independent predictors of quality of life. The overall regression model was 
significant (F½6; 96 ¼ 4:92; p50:001), and accounted for 24% of the variance in 
quality of life. 
 
 
DISCUSSION 
 
The methodology of health related quality of life measurement is now well 
established in cancer research. As a result, this concept is an important 
reference point for enquiry into those attributes that contribute to the perception and 
experience of life. Oncology research has focused on a variety of health related 
attributes that contribute to quality of life and indeed the measurement of these 
attributes has also been applied to the general community (Hjermstad et al., 1998). In 
the current study, a scale of quality of life was developed which emphasized 
happiness and satisfaction. The internal consistency of this scale fell within the 
conventionally accepted limits of reliability (Nunnally, 1978). At the time of this 
study (Yates et al., 1993), instruments were already available from the literature but, 
in general, these instruments did not interpret global quality of life in terms of 
happiness and satisfaction. Since that time, other scales of quality of life have been 
developed and utilized in cancer research. However, many scales are narrow in focus, 
interpreting quality of life in a health related manner, typically with an emphasis on 
symptoms and functioning based on a time frame of the immediate past (Aaronson et 
al., 1993; Testa and Simonson, 1996). 
 
In considering illusory attitudes and beliefs in the context of quality of life, the 
validity of the current instrument of global quality of life was supported by a 
correlation with accepted measures. For example, there was a strong correlation 
between ECOG performance status and mean and good quality of life scores (Table 
6). These results are consistent with other reports of this association 
(Schipper et al., 1984; Selby et al., 1984; Morrow et al., 1992; Bliss et al., 1992). In 
this study, clinicians rated whether the symptom status of the patient was improving, 
stable or worse since the last assessment. In general, there was a correlation 
between the physician’s assessment of the status of symptoms and quality of life 
scores (Table 6). This correlation is supported by the results of other studies of the 
impact of cancer related symptoms (Sarna, 1993) and side-effects of treatment (Pater 
et al., 1992; Lindley et al., 1992; O’Brien et al., 1993) on the measurement of quality 
of life. 
 
As part of the standard of clinical care, patients were reviewed regularly and were 
informed verbally about the status of their cancer. This information included 
discussion about the incurability of the cancer, the palliative goal of treatment, the on-
going progress of their cancer, and the response to treatment. Despite this 
information, only 45 patients (31%) indicated they believed that their cancer was 
incurable (Table 4). One possible explanation of this observation is inadequate verbal 
communication. However, none of the patients who believed that their cancer was 
incurable reported that the doctor had stated that the cancer was curable. In the current 
study, 39 patients (27%) believed that the cancer was curable. This result is similar to 
the study of Mackillop et al. (1988) who reported a belief in curability by 33% of 
patients with metastatic cancer who had been informed of the palliative goal of 
treatment. Of the patients who believed that their cancer was curable, 16 (41%) 
reported that their doctor had stated that the cancer was curable, but another 15 
patients (38%) reported that their doctor had stated that the cancer was incurable. The 
pattern of this latter response indicates that some patients acknowledged conflicting 
views about the curability of their cancer. The development of positive attitudes and 
patterns of belief and behaviour to cope with a negative event are well documented in 
psychosocial research, and other studies have documented a belief in curability by 
patients with advanced cancer (Butow et al., 1999; Richardson et al., 2000) since 
the time of the report by McKillop et al. (1988) and the current study (Yates et al., 
1993). For patients with advanced cancer, the expression of uncertainty and 
conflicting beliefs are consistent with the use of illusion (Taylor et al., 1989) as an 
adaptive process to deal with the prospect of a fatal illness. The use of alternative 
treatments also supports the importance of illusory beliefs for some patients since 
these approaches are typically promoted as a cure for cancer. Committed users of 
alternatives to conventional medical treatments in this study were more likely to 
believe in the curability of their cancer than patients who did not use alternative 
treatments or who made only minimal alternative changes to their lifestyle 
(Table 5).  
The development of illusions, with a bias towards a positive self-perception, is now 
recognized as a feature of normal psychological behaviour (Taylor and Brown, 1988). 
Positive illusions allow individuals to see themselves as different from others and can 
lead to an unrealistic self-assessment, an unduly optimistic view of the future and an 
exaggerated belief in the ability to control environmental events. The consequences 
of positive illusions can include happiness and productive social activity, both 
important attributes contributing to the perception of quality of life. For patients with 
advanced cancer, support for this notion is provided by the distribution of quality of 
life scores within the scale of belief in curability (Table 6). Quality of life scores and 
the likelihood of a good quality of life were strongly associated with the scale of 
belief in curability. 
 
To date, there has been little evaluation of the factors that drive illusory beliefs in 
patients with advanced cancer, but the expectation of benefit from treatments of 
minimal (Slevin et al., 1990) and unproven (Daugherty et al., 1995; Bagenal 
et al., 1990) efficacy suggests that a desire for cure and a strongly developed will to 
live are important attributes that influence the behaviour of some  patients. In the 
current study, the scale of will to live showed a significant association with quality 
of life scores (Table 6). This finding supports the view that positive illusory attitudes 
and beliefs represent a means of coping with a life-threatening event for some 
patients. In psychosocial research, patterns of coping with stressful daily events by 
healthy people and by patients with cancer recognize a variety of individual 
responses, some realistic and others illusory (Dunkel-Schetter et al., 1992; Folkman et 
al., 1986). In the current study, the relationship between quality of life scores and 
both an inappropriate belief in curability and a strongly developed will to live 
strengthens the interpretation that the measurement of quality of life by some patients 
was not based on a realistic appraisal of their situation. 
 
In the current study, the relationship of health related measures and global quality of 
life has been documented and, in addition, an illusory domain, characterized by 
certain beliefs and attitudes, has been identified as a potentially important contributor 
to the experience of life by some patients with advanced cancer. Within this illusory 
domain, will to live was strongly associated with global quality of life. Will to live is 
a concept that has received little attention in psychosocial research (Carmel and 
Mutran, 1997). Patients with advanced cancer are an ideal group to test the concept of 
will to live because they face the prospect of dying but, if they respond to palliative 
treatment, can postpone death. In contrast to quality of life which is a pyschosocial 
construct describing a bigger picture of the experience of life, will to live is a more 
fundamental concept and is not as readily amenable to description or measurement. 
For example, any attempt to interpret will to live as a fundamental driving force of 
existence inevitably leads towards philosophical debate and uncertainty. One possible 
interpretation is that will to live is a pattern of behaviour that is reflex driven 
and unthinking. In this model, will to live is seen as a manifestation of instinct}an 
action that takes precedence over any thought of the consequences of that action. 
From this perspective, will to live drives those aspects of thought that create and 
shape illusions. An alternative model sees will to live as a chosen course of action, 
part of a thought process which blends into a constellation of psychological attributes 
that create illusions. As a result, will to live is part of a psychological adaptive 
strategy to a life threatening illness. Each model is plausible but subject to 
controversy as progressively more complex explanations penetrate deeper into the 
differing philosophical viewpoints. Does will to live fit the philosophical 
interpretation of will as a fundamental, perhaps even aimless, metaphysical force 
or is will to live part of a rationalist explanation of being? The measurement of the 
concept of will to live in the current study does not provide a method 
of addressing the place of will to live in the hierarchy of being. Nevertheless, for these 
patients who faced the prospect of death, will to live emerged as a relevant force in 
their lives. Not surprisingly, these patients scored will to live towards the positive end 
of the scale. Distortion away from a normal distribution could be interpreted as a 
feature of innate behaviour or a fundamental metaphysical force, but equally this 
skewed distribution may simply be part of an adaptive psychological process. 
Furthermore, neither explanation is necessarily mutually exclusive. Despite the 
limitation of trying to identify the place of will to live in the hierarchy of being and 
survival, this concept appears to be an important component of the positive illusions 
that some patients exhibited in this study. So strong was this concept that both will to 
live and performance status remained correlated with quality of life scores after 
adjustment for other variables (Table 6). 
 
Caution needs to exercised in the interpretation of these results. A multitude of factors 
contribute to the perception of quality of life and a potential source of error is 
incorrect attribution of a causal association of the variables under study. If 
attitudinal factors include the presence of unrealistic belief systems, there are several 
important clinical implications. A subjective response to palliative treatment might 
reinforce an illusion of cure, and therefore a good quality of life might be a surrogate 
measure of a patient’s will to survive a cancer. If this is the case, the use of quality of 
life as an end point of clinical trials of cancer treatments could be viewed as  
compromised because the measurement by some patients will be influenced by 
factually incorrect beliefs. On the other hand, there could be important positive 
outcomes as a result of illusory beliefs and a strongly developed will to live. For 
example, physician and patient rated quality of life measures are associated with 
higher scores and better survival in metastatic breast cancer (Coates et al., 1992; 
Sideman et al., 1995) and melanoma (Coates et al., 1993). Irrespective of these 
practical implications, the results of this study indicate that illusory attitudes and 
beliefs, long recognized in psychosocial research, can be measured and appear to be 
an important domain contributing to the perception of quality of life in some patients 
with advanced cancer. 
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